Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 01, 2026
TickeronGET DAILY SIGNALS
Horizon Kinetics Medical ETF (MEDX): Assessing the Path to a $43 Target

Horizon Kinetics Medical ETF (MEDX): Assessing the Path to a $43 Target

Key Takeaways

  • The $43 target is not an analyst consensus on the ETF itself but a publicly available 12-month price objective derived from the weighted average analyst price targets on MEDX's underlying holdings.
  • TipRanks' ETF forecast, built from targets on the fund's 31 holdings, shows an average of about $43.29, with a range of roughly $32.45 to $52.67.
  • At a recent price near $36, reaching $43 would require upside of roughly 19–20%, a substantial move for a diversified healthcare fund.
  • The portfolio is 100% healthcare, with heavy weight in large-cap pharmaceuticals such as Eli Lilly, AbbVie, Novartis, and Johnson & Johnson.
  • The strongest supporting factors are the long-term growth of global drug spending and exposure to high-margin branded pharmaceuticals.
  • The biggest risks are concentration in a few large holdings, the fund's small AUM, and regulatory or pipeline setbacks in healthcare.
  • For more detail on the fund's Major News and Today's Price Move, its Forecast, and Earnings of key holdings, explore these dedicated pages.

How the $43 Target Came About

Because MEDX is an ETF, there is no direct stock price target published by sell-side analysts on the fund itself. Instead, the $43 figure reflects public discussion and third-party research that converts analyst price targets on the fund's holdings into an implied fund-level objective. TipRanks publishes an ETF forecast for MEDX that aggregates 12-month price targets on the 31 stocks it holds, producing an average of about $43.29, with a low near $32.45 and a high near $52.67. This derived figure is a weighted reflection of Wall Street's views on large holdings such as Eli Lilly (LLY) and AbbVie (ABBV), not a formal consensus rating on MEDX. Rounded for readability, this gives a central target of $43. I also checked this using Tickeron’s AI Screener to see how the holdings stack up against peers.

Current Market Position and Path Toward the Target

MEDX has recently traded in the mid-$30s, near $36, with a 52-week range spanning roughly $29 to $37.90. Reaching $43 from that level would require an advance of about 19–20%, which qualifies as a substantial move. The fund's largest positions — including Eli Lilly at nearly 20% of assets, AbbVie at roughly 10%, and Novartis (NVS) and Johnson & Johnson (JNJ) at roughly 6% each — mean the path toward $43 depends heavily on sustained strength in branded pharmaceuticals. Additional positions in Amgen (AMGN), Merck (MRK), Bristol-Myers Squibb (BMY), and Pfizer (PFE) broaden the exposure but keep the fund firmly tied to the healthcare sector's fortunes.

What Could Support a Move Toward the Target

Several factors could support upside. Global healthcare spending is widely projected to keep rising over the long term, favoring companies with patented, high-margin drugs. MEDX's managers emphasize first-line pharmaceuticals and biologics with strong barriers to entry, a style that benefits from durable pricing power and pipeline innovation. Continued strength in obesity, oncology, and immunology franchises — areas where Eli Lilly, AbbVie, and others hold leading positions — could lift the fund's net asset value. A rotation back toward defensive, cash-generative healthcare names during periods of macroeconomic uncertainty could also provide a tailwind, as could favorable interest-rate conditions that reduce the appeal of fixed income relative to dividend-paying healthcare equities.

What Could Prevent the Target From Being Reached

Concentration is the clearest structural risk. With Eli Lilly alone representing roughly a fifth of assets, a single-stock setback could weigh materially on the fund. Regulatory developments, drug-pricing reform, patent expirations, and clinical-trial failures can compress valuations across the sector. The fund's modest AUM of roughly $17 million and thin average daily trading volume can also produce wider bid-ask spreads and make the fund less liquid than larger healthcare ETFs. Finally, a broader shift in investor preference toward growth sectors such as technology, or a sell-off in defensive names, could leave MEDX trading below its recent highs for an extended period.

Technical Levels and Market Structure

On a technical basis, the fund's 52-week high near $37.90 represents an important resistance level; a decisive move above that zone would be a necessary first step before the $43 objective comes into focus. The low-to-mid-$30s — around the fund's 52-week low of roughly $29 and the more recent support near $30.79 — marks a key area where buyers have previously stepped in. A round-number level such as $40 could also act as a psychological hurdle. The fund remains in a broad uptrend over the past year, but its path toward the target depends on holding above these support zones while clearing prior highs.

Time Horizon and What Investors Should Monitor

The $43 objective reflects a roughly 12-month research horizon, matching the typical window of the underlying analyst price targets used to derive it. Investors should watch quarterly earnings and pipeline news from the fund's largest holdings — particularly Eli Lilly and AbbVie — along with broader healthcare policy developments and drug-pricing legislation. Interest-rate decisions from the FOMC and sector fund flows can also influence how healthcare equities are valued. Any material change in analyst targets on major holdings would directly shift the implied fund-level objective, so monitoring revisions is essential.

Using AI Daily Buy/Sell Signals in Practice

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For an instrument like MEDX, where much of the story is driven by underlying holdings and sector momentum, these automated signals can help traders spot changing trends more efficiently, monitor positions, and surface new opportunities without manually scanning hundreds of charts. I find them useful as one input alongside fundamental review when evaluating healthcare exposure.

Final Assessment

The $43 target for MEDX is a substantial objective requiring roughly 19–20% upside from recent levels near $36. It is grounded in the weighted analyst price targets on the fund's underlying holdings rather than in a consensus rating on the ETF itself, with an implied range spanning from the low $30s to the low $50s that reflects genuine disagreement about the healthcare sector's near-term direction. Support could come from durable pharmaceutical demand and strength in key franchises, while concentration, regulatory risk, and limited liquidity represent the principal obstacles. Whether MEDX approaches $43 will ultimately depend on how its largest holdings perform and whether healthcare equities attract renewed investor interest, and no outcome should be treated as guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MEDX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


MEDX in upward trend: 10-day moving average broke above 50-day moving average on October 23, 2026

The 10-day moving average for MEDX crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDX advanced for three days, in 181 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

MEDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 158 of 189 cases where MEDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for MEDX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 20 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MEDX as a result. In 45 of 62 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for MEDX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 25 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

MEDX moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB).

Industry description

The investment seeks to provide long-term growth of capital. The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.

Market Cap

The average market capitalization across the Horizon Kinetics Medical ETF (MEDX) ETF is 146.84B. The market cap for tickers in the group ranges from 740.36K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is DCOY at 740.36K.

High and low price notable news

The average weekly price growth across all stocks in the Horizon Kinetics Medical ETF (MEDX) ETF was -6%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was 6%. NTLA experienced the highest price growth at 3%, while LTRN experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Horizon Kinetics Medical ETF (MEDX) ETF was 47%. For the same stocks of the ETF, the average monthly volume growth was 58% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 38
Price Growth Rating: 51
SMR Rating: 69
Profit Risk Rating: 67
Seasonality Score: 14 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.